Introduction
Pulmonary hypertension (PH) is a common complication of left heart disease (LHD) that results in severe symptoms and exerts a negative impact on outcome.
1 -4 PH develops in LHD in response irreversible pulmonary vascular disease. Recently, the haemodynamic definitions of PH-LHD have been modified in the European guidelines to better approach the characteristics required to reflect the presence of pulmonary vasculopathy. Two different types of post-capillary PH have been identified, i.e. isolated post-capillary pulmonary hypertension (Ipc-PH) and combined post-capillary and pre-capillary pulmonary hypertension (Cpc-PH). 5, 6 A reversibility test is recommended in PH-LHD patients who undergo diagnostic right heart catheterization if the patients have to be evaluated for heart transplantation, as the absence of reversibility precludes the eligibility for heart transplantation. 7 -9 Studying patients with PH-LHD who have undergone an acute vasodilator challenge is a good opportunity to understand to what extent the haemodynamic definitions of post-capillary PH are associated with the presence of a reversible component (possibly vasoconstriction) or with the presence of a fixed component (possibly treatment-resistant pulmonary vasculopathy).
The purpose of the study was to compare the vasodilator response in Ipc-PH and Cpc-PH patients. We predicted a greater reversibility in Ipc-PH patients than in Cpc-PH patients on the basis of the hypothesis that irreversible pulmonary vasculopathy is the main determinant of the superimposed pre-capillary component in Cpc-PH patients. In addition, we evaluated whether new and old haemodynamic definitions of post-capillary PH imply a different reversibility of PH.
Methods

Study patients
The study is a retrospective analysis of 156 heart failure patients with reduced ejection fraction and PH (HFrEF-PH) hospitalized for heart failure management and/or heart transplantation evaluation in three referral centres in Northern Italy. The inclusion criteria were: aetiology due to dilated cardiomyopathy or ischaemic or hypertensive heart disease (ischaemic aetiology was defined on the basis of documented previous myocardial infarction or significant disease on coronary arteriography); PH defined as mean pulmonary artery pressure (PAP) ≥ 25 mmHg at right heart catheterization; and reversibility testing during routine right heart catheterization. Exclusion criteria were: acute heart failure patients; heart failure due to valvular heart disease or any previous valvular heart surgery, implant of a cardiac resynchronization device in the previous 6 months, diagnosis of severe chronic obstructive pulmonary disease, and a history of pulmonary embolism; patients receiving inotropic agents at presentation were also excluded from the study. The investigation conforms to the principles outlined in the Declaration of Helsinki. Patients signed an informed consent to collect data for scientific purposes, and the Ethics Committee of Fondazione IRCCS Policlinico San Matteo gave approval for the analysis (protocol no. 08013401/14).
Right heart haemodynamic evaluation
Right heart catheterization was performed after treatment optimization using a balloon tipped catheter which was inserted transcutaneously under echographic control through the right internal jugular vein and advanced into the pulmonary artery. The following haemodynamic parameters were measured: pulmonary artery wedge pressure (PAWP); systolic, diastolic and mean PAP; pulmonary pulse pressure (PP); cardiac output (CO, calculated by thermodilution as no patient had severe tricuspid regurgitation); cardiac index (CI); stroke volume (SV, obtained dividing CO by heart rate); and right atrial pressure (RAP). Derived parameters were: transpulmonary gradient (TPG = mean PAP − PAWP); diastolic pulmonary gradient (DPG = diastolic PAP − PAWP); pulmonary vascular resistance (PVR), calculated as TPG/CO; pulmonary arterial compliance (PCa), estimated by dividing the blood volume driven from each heart beat in the pulmonary vascular tree, namely the SV, by the corresponding change in PAP: PCa ≈ SV/PP (mL/mmHg); right ventricular stroke work index (RVSWi), calculated as SV index × (mean PAP − RAP) × 0.0136 gm-m/m 2 /beat. Patients were classified in three ways. Pressure curves were analysed manually, averaging data obtained over at least three (or five in case of atrial fibrillation) cardiac cycles selected at end-expiration; preliminary informed consent was obtained.
According to the 2015 European guidelines, Cpc-PH was defined as mean PAP ≥25 mmHg, PAWP >15 mmHg, DPG ≥ 7 mmHg and/or PVR > 3 wood units (WU) and Ipc-PH as mean PAP ≥25 mmHg, PAWP >15 mmHg, DPG < 7 mmHg and/or PVR ≤ 3 WU. 6 According to another recent suggestion, Cpc-PH was defined as mean PAP ≥25 mmHg, PAWP >15 mmHg and DPG ≥7 mmHg and Ipc-PH as mean PAP ≥25 mmHg, PAWP >15 mmHg and DPG < 7 mmHg. 10, 11 Finally, 'passive' or 'reactive' PH was defined on the basis of TPG values, i.e. ≤12 mmHg vs. >12 mmHg as per the 2009 European guidelines.
Acute vasodilator challenge
After baseline haemodynamic data were acquired, an intravenous bolus infusion of nitrate was performed: 26 patients received nitroglycerin, starting at a dose of 0.1 mg and 130 patients received nitroprusside starting at a dose of 10 μg/min; the dose of the vasodilator was rapidly titrated until there was: (i) normalization in PAP; (ii) reduction in systolic blood pressure to <90 mmHg; or (iii) patient intolerance. Haemodynamic measurements were then immediately repeated. It has to be acknowledged that the criteria used to define reversibility in this patient population are still arbitrary; to the aim of the present study, patients were defined responders to the vasodilator challenge if PVR decreased below 2.5 WU and systolic blood pressure did not decrease below 85 mmHg. 7
Follow-up
The endpoint of survival analysis was all-cause mortality. Heart transplantation was considered as a censoring event. Survival data were obtained through follow-up visits or, in the case of missed visits, by telephone contact.
Statistical analysis
Baseline categorical variables were displayed as count (percentage) and compared with the 2 test. Baseline continuous variables and right heart catheterization parameters were expressed as mean ± standard deviation or median (interquartile range) and compared between PH groups with Student's t-test or Wilcoxon rank-sum test, according to their distribution. Right heart catheterization parameters before and after vasodilatation test within individual subjects were compared with analysis of variance (ANOVA) or non-parametric ANOVA 12 for longitudinal studies consistently: time effect, group effect, and the interaction between time and group on each parameter of interest were assessed. Time-to-death was explored by Kaplan-Meier analysis, differences in outcome were compared using the log-rank test, hazard ratio (HR) and 95% confidence interval (CI) was estimated by fitting a Cox proportional hazard regression model. A two-sided P-value ≤0.05 was considered significant. Data were analysed in R version 3.30.
Results
The baseline characteristics of Cpc-PH (n = 106) and Ipc-PH (n = 50) patients are shown in Table 1 . No patient received drugs approved for pulmonary arterial hypertension. At echocardiography, Cpc-PH patients had a worse right ventricular to pulmonary circulation coupling as evidenced by the fact that the tricuspid annular plane systolic excursion (TAPSE)/systolic PAP ratio was lower or less favourable in Cpc-PH than in Ipc-PH. Only one out of 30 patients (3.3%) with high DPG had low PVR; 75 out of 126 patients (59.5%) with low DPG had high PVR.
Right heart haemodynamics in combined post-capillary and pre-capillary pulmonary hypertension and isolated post-capillary pulmonary hypertension patients
At baseline, Cpc-PH patients had a more advanced haemodynamic profile ( the two groups but the haemodynamic profile of Cpc-PH patients was characterized by lower systemic blood pressure, CO and PCa and by higher pulmonary pressures and gradients and PVR as compared with Ipc-PH patients ( Table 2 ). The changes in haemodynamic parameters in Cpc-PH vs. Ipc-PH patients are shown in Table 3 and Figure 1 . PVR, TPG and DPG improved significantly more in Cpc-PH patients whereas PCa improved significantly more in Ipc-PH patients (all P < 0.001 for interaction) ( Table 3 and Table 4 ). As illustrated in Figure 2 , despite the greater improvement in gradients and resistances, Cpc-PH patients remained in an unfavourable portion of the inverse hyperbolic relationship between PVR and PCa.
Right heart haemodynamics in patients with high/low diastolic pulmonary gradient and high/low transpulmonary gradient
The haemodynamic effects of vasodilator administration were compared in patients with DPG ≥7 mmHg (n = 30) vs. patients with DPG < 7 (n = 126) and in patients with TPG > 12 mmHg (n = 74) vs. patients with TPG ≤ 12 (n = 82). The delta values in haemodynamic parameters in high vs. low DPG are shown in Table 5 and are similar to those observed in Cpc-PH and Ipc-PH patients. The delta values in haemodynamic parameters in high vs. low TPG are shown in Table 6 ; in this case the improvements in PVR and in TPG were significantly higher in low TPG than in high TPG patients. Data are displayed as mean ± standard deviation. BP, blood pressure; CI, cardiac index; CO, cardiac output; Cpc-PH, combined post-capillary and pre-capillary pulmonary hypertension; DPG, diastolic pulmonary gradient; HR, heart rate; Ipc-PH, isolated post-capillary pulmonary hypertension; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PCa, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWi, right ventricular stroke work index; TPG, transpulmonary gradient. Data are displayed as mean ± standard deviation, or median (interquartile range). All Δ are calculated as: (baseline value − vasodilator value). BP, blood pressure; CI, cardiac index; CO, cardiac output; Cpc-PH, combined post-capillary and pre-capillary pulmonary hypertension; DPG, diastolic pulmonary gradient; HR, heart rate; Ipc-PH, isolated post-capillary pulmonary hypertension; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PCa, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWi, right ventricular stroke work index; TPG, transpulmonary gradient. 
Responders to vasodilator challenge according to pulmonary hypertension definition
Follow-up
Sixty-three patients died during the median follow-up period of 23 months. Survival was significantly poorer in Cpc-PH than in Ipc-PH patients (Figure 3 ). Supplementary information online Table  S1 and Table S2 show the haemodynamic data in survivors and in non-survivors both in Cpc-PH and in Ipc-PH patients (follow-up data were available in 151 out of 156 patients). In Cpc-PH patients, the haemodynamic profile of survivors was characterized by a lower systolic PAP and a lower RVSWi after vasodilator administration (P < 0.01), whereas in Ipc-PH patients the haemodynamic profile of survivors was characterized by a lower RAP both at baseline and after acute vasodilatation (P < 0.01). Supplementary information online online Figure S1 shows that survival was significantly poorer in non-responder patients than in responder patients.
Discussion
To our knowledge, this study is the first to try to establish a relationship between different haemodynamic definitions of post-capillary PH and the haemodynamic response to an acute vasodilator administration. The first result is that although a greater reversibility in response to acute vasodilator administration was observed in Cpc-PH patients than in Ipc-PH patients, 
Pulmonary hypertension-left heart disease
The pathogenesis of PH occurring as a complication of LHD is still largely unknown. In particular, the development of irreversible vascular remodelling is a dreaded event since it determines a stable increase in right ventricular afterload, which worsens prognosis leading to right ventricular failure, precludes organ transplantation, and has no specific medical therapy. Recently, the haemodynamic definitions of PH-LHD have been modified in the European guidelines to better approach the characteristics required to determine pulmonary vascular disease. Definitions now include the DPG and exclude the TPG. However, the role of DPG is controversial, in particular from the prognostic point of view. 10,11,13 -17 Nonetheless, these limitations should not affect the diagnostic value of DPG, as a variable can be diagnostic yet fail as a prognostic biomarker.
18
To understand to what extent the new haemodynamic definitions are associated with the presence of a reversible component (possibly vasoconstriction) or with the presence of a fixed component (possibly treatment-resistant pulmonary vasculopathy), we studied patients with PH-LHD who had undergone an acute vasodilator challenge. Reversibility of PH after acute vasodilator administration has been the objective of several previous studies, but it has never been related to the recent haemodynamic definitions of Group 2 PH. Δ are mean (standard deviation) of per cent variation after vasodilator challenge. BP, blood pressure; CI, cardiac index; CO, cardiac output; HR, heart rate; DPG, diastolic pulmonary gradient; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PCa, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWi, right ventricular stroke work index; TPG, transpulmonary gradient. Δ are mean (standard deviation) of per cent variation after vasodilator challenge. BP, blood pressure; CI, cardiac index; CO, cardiac output; HR, heart rate; DPG, diastolic pulmonary gradient; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PCa, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWi, right ventricular stroke work index; TPG, transpulmonary gradient.
Vasodilator challenge in combined post-capillary and pre-capillary pulmonary hypertension and in isolated post-capillary pulmonary hypertension
In the present series of patients, right heart haemodynamics improved significantly more in Cpc-PH that in Ipc-PH patients. This substantial improvement in haemodynamic parameters in Cpc-PH . patients is in agreement with a recent study showing that in patients with advanced heart failure undergoing implantation of a left ventricular assist device, all pre-capillary markers of right heart haemodynamics normalize within 72 h. 21 However, it must be noticed that the greater vasodilation in Cpc-PH patients was not associated with a normalization of the haemodynamic profile. As illustrated in Figure 2 , after vasodilatation, despite the statistically significant improvement in PVR and PCa, Cpc-PH patients 22 -24 These data would therefore indicate that either the pre-capillary component in Cpc-PH patients is in larger part determined by reversible vasoconstriction rather than by treatment-resistant fixed components (i.e. pulmonary vasculopathy) or that in Cpc-PH patients there is a form of pulmonary vascular disease that is potentially treatable. Definitely, we need more studies analysing pulmonary histopathology in Group 2 PH patients to solve this issue. 25 As a matter of fact, survival was poorer in Cpc-PH patients than in Ipc-PH . The TAPSE/systolic PAP ratio was less favourable in Cpc-PH than in Ipc-PH patients and this suggests that a reduced right ventricular-pulmonary vascular coupling could be one explanation for dismal outcomes. In addition, the new haemodynamic definitions of post-capillary PH did not provide a greater specificity in the identification of patients with irreversible PH as compared with previous definitions since the proportion of responders to vasodilator administration was substantially similar in Cpc-PH patients, DPG ≥7 mmHg patients and TPG >12 mmHg patients.
There are several potential clinical implications of these data. First of all, a baseline description of the haemodynamic profile cannot be used to trace the presence of irreversible pulmonary vasculopathy. This does not mean that haemodynamic thresholds for high risk surgery are useless (e.g. in the selection of candidates to heart transplant or ventricular assist devices) but that the link between haemodynamic thresholds and pulmonary vascular disease remains elusive and that we have to reconsider the reasons why these are associated with poorer survival since irreversible pulmonary vasculopathy may not be the only reason. More studies focusing on pulmonary histopathology in chronic pulmonary venous hypertension are necessary to establish correlations between right heart haemodynamics and lung histology. Second, in the absence of proven therapies for PH due to LHD, patients with Cpc-PH are often considered unresponsive to conventional vasodilator therapy and are treated with drugs approved for pulmonary arterial hypertension; the demonstration of a substantial amount of vasodilatation in Cpc-PH patients (at least in an acute condition) has important consequences both for clinicians, who should be discouraged to treat patients with off label therapies, and for researchers, who should be encouraged to test new therapies targeting the pulmonary circulation in such patients. Interestingly, PCa was the only haemodynamic parameter consistent with the hypothesis of an irreversible pulmonary vasculopathy in Cpc-PH patients; in fact, PCa improved to a greater extent after vasodilator challenge in Ipc-PH than in Cpc-PH patients. Further studies are necessary to verify the potential usefulness of low PCa values in identifying heart failure patients at high risk after organ transplantation or those with a low a priori likelihood of a positive clinical response to vasodilator drugs.
Remarkably, none of the haemodynamic parameters which are used to characterize the haemodynamic profile (either at baseline or after vasodilator challenge) was different between survivors and non-survivors. In the Cpc-PH group survivors had a lower systolic PAP and a lower right ventricular work after vasodilator administration than non-survivors. This observation could be interpreted considering that a lower work (and therefore a lower O 2 consumption) of the right ventricle is associated with better survival and it is in agreement with older reports demonstrating that, in PH-LHD patients, the improvement in right ventricular performance following afterload reduction (i.e. right ventricular reserve) is a better associated outcome rather than the reduction in vascular resistance per se. 27, 28 In the Ipc-PH group, survivors had a lower RAP both at baseline and after vasodilatation; an elevated RAP is an indicator of right ventricular dysfunction, which is a most important haemodynamic parameter in all patients with advanced heart failure.
29,30
Limitations
The results of this study strictly apply to heart failure patients with advanced left ventricular systolic dysfunction and cannot be extrapolated to other types of heart failure patients such as those with acute heart failure or with preserved or mildly reduced left ventricular ejection fraction as defined by the most recent European guidelines. 31 The relevance of the present data in other fields of cardiology (i.e. valvular heart disease or management of acute decompensated heart failure) is also unknown. Whether there are vasodilator treatments that could be effective in reversing vasoconstriction also on a long-term basis in Cpc-PH patients is beyond the scope of the present study. Reversibility of PH in LHD is still a rather controversial matter. Reversibility may be tested with different drugs and the criteria used for its definition in this patient population are still arbitrary; in addition, it is unknown whether it has clinical or prognostic significance in the general population of heart failure patients. However, clarification of these issues was out of the scope of the present study. Standardization of right heart catheterization procedure may be difficult, however the three centres participating in the present study tightly interacted on a daily basis, sharing routine activity, procedures and patients' follow-up. Additionally, this study is a retrospective analysis of HFrEF-PH patients and was not designed to evaluate survival nor to evaluate the events after heart transplantation, therefore the differences in the haemodynamic profile after vasodilatation between survivors and non-survivors in Cpc-PH and Ipc-PH patients must be considered with caution and deserve to be confirmed prospectively. Finally, considering that the definition of Cpc-PH is still controversial and that the combination of increased DPG and increased PVR has been suggested for more robust Cpc-PH phenotyping, future studies involving larger populations of Cpc-PH patients should aim at evaluating the response to vasodilator challenge in this specific subgroup as well.
15,32
In conclusion, in HFrEF-PH patients, a remarkable amount of reversibility of PH was observed in Cpc-PH patients despite the fact that even after vasodilatation, such patients remained in the unfavourable (flat) region of the PCa vs. PVR relationship. In addition, the new haemodynamic definitions of post-capillary PH do not provide a greater specificity in the identification of patients with irreversible PH as compared with previous definitions. These data imply that the relationship between baseline right heart haemodynamics and pulmonary vascular disease remains difficult to assess. This should drive clinicians to treat Cpc-PH patients intensively with standard therapies and investigators to design ad hoc clinical trials that explore the clinical effects of vasodilator therapy.
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